Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

CLASS ACTION UPDATE for DNMR, SPCE and ATHA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

SPCE, ATHA, DNMR

NEW YORK, NY / ACCESSWIRE / June 29, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

DNMR Shareholders Click Here: https://www.zlk.com/pslra-1/danimer-scientific-inc-loss-submission-form?prid=17243&wire=1
SPCE Shareholders Click Here: https://www.zlk.com/pslra-1/virgin-galactic-holdings-inc-loss-submission-form?prid=17243&wire=1
ATHA Shareholders Click Here: https://www.zlk.com/pslra-1/athira-pharma-inc-loss-submission-form?prid=17243&wire=1

* ADDITIONAL INFORMATION BELOW *

Danimer Scientific, Inc. (NYSE:DNMR)

DNMR Lawsuit on behalf of: investors who purchased October 5, 2020 - May 4, 2021
Lead Plaintiff Deadline : July 13, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/danimer-scientific-inc-loss-submission-form?prid=17243&wire=1

According to the filed complaint, during the class period, Danimer Scientific, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Danimer had deficient internal controls; (ii) as a result, the Company had misrepresented, inter alia, its operations' size and regulatory compliance; (iii) Defendants had overstated Nodax's biodegradability, particularly in oceans and landfills; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Virgin Galactic Holdings, Inc. (NYSE:SPCE)

SPCE Lawsuit on behalf of: investors who purchased October 26, 2019 - April 30, 2021
Lead Plaintiff Deadline : July 27, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/virgin-galactic-holdings-inc-loss-submission-form?prid=17243&wire=1

According to the filed complaint, during the class period, Virgin Galactic Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) for accounting purposes, Social Capital Hedosophia Holdings Corp.'s ("SCH") warrants were required to be treated as liabilities rather than equities; (ii) Virgin Galactic had deficient disclosure controls and procedures and internal control over financial reporting; (iii) as a result, the Company improperly accounted for SCH warrants that were outstanding at the time of the business combination; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Athira Pharma, Inc. (NASDAQ:ATHA)

This lawsuit is on behalf of investors who purchased Athira Pharma, Inc. (NASDAQ: ATHA) between September 18, 2020 and June 17, 2021 and/or purchased common stock in or traceable to the Company's registration statement issued in connection with the Company's September 2020 initial public offering priced at $17.00 per share.
Lead Plaintiff Deadline : August 24, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/athira-pharma-inc-loss-submission-form?prid=17243&wire=1

According to the filed complaint, (1) the research conducted by Defendant Kawas, which formed the foundation for Athira's product candidates and intellectual property, was tainted by Kawas' scientific misconduct, including the manipulation of key data through the altering of Western blot images; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/653550/CLASS-ACTION-UPDATE-for-DNMR-SPCE-and-ATHA-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today